BPG is committed to discovery and dissemination of knowledge
Featured Articles
7/21/2021 9:37:44 AM | Browse: 13 | Download: 34
Publication Name World Journal of Clinical Oncology
Manuscript ID 63832
Country/Territory Russia
2021-02-03 15:15
Peer-Review Started
2021-02-03 15:16
To Make the First Decision
Return for Revision
2021-03-31 04:59
2021-04-04 12:47
Second Decision
2021-06-03 08:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-06-03 12:02
Articles in Press
2021-06-03 12:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
2021-06-13 21:00
Typeset the Manuscript
2021-07-20 04:42
Publish the Manuscript Online
2021-07-21 09:30
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
Manuscript Source Invited Manuscript
All Author List Evgeny Imyanitov and Anna Sokolenko
Funding Agency and Grant Number
Funding Agency Grant Number
Ministry of Science and Higher Education of the Russian Federation 15-2020-789
Corresponding Author Evgeny Imyanitov, MD, Professor, Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Pesochny, Leningradskaya str. 68, Saint-Petersburg 197758, Russia. evgeny@imyanitov.spb.ru
Key Words BRCA1/2 mutations; platinum-based therapy; Poly (ADP-ribose) polymerase inhibitors; drug resistance; Secondary mutations; Intratumoral heterogeneity; Neoadjuvant therapy
Core Tip BRCA1/2-associated tumors are highly sensitive to platinum compounds and poly (ADP-ribose) polymerase inhibitors, however they eventually acquire resistance to this type of therapy. Restoration of BRCA1/2 function via the second mutation is the most known mechanism of tumor adaptation to the therapeutic pressure. Some studies demonstrate that even chemonaive BRCA1-driven tumors contain a small fraction of BRCA1-proficient cells, suggesting that the loss of the remaining allele of this gene is not the first event in tumor pathogenesis. These pre-existing platinum-resistant cells rapidly repopulate tumor mass during neoadjuvant therapy for ovarian cancer and explain inevitability of the disease relapses after seemingly successful surgical debulking.
Publish Date 2021-07-21 09:30
Citation Imyanitov E, Sokolenko A. Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. World J Clin Oncol 2021; 12(7): 544-556
URL https://www.wjgnet.com/2218-4333/full/v12/i7/544.htm
DOI https://dx.doi.org/10.5306/wjco.v12.i7.544
Full Article (PDF) WJCO-12-544.pdf
Full Article (Word) WJCO-12-544.docx
Manuscript File 63832-Review-FilipodiaCL .docx
Answering Reviewers 63832-Answering reviewers.pdf
Audio Core Tip 63832-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 63832-Conflict-of-interest statement.pdf
Copyright License Agreement 63832-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 63832-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate 63832-Language certificate.pdf
Peer-review Report 63832-Peer-review(s).pdf
Scientific Misconduct Check 63832-Bing-Ma YJ-1.jpg
Scientific Misconduct Check 63832-Bing-Liu M-2.png
Scientific Misconduct Check 63832-Scientific misconduct check.pdf
Scientific Editor Work List 63832-Scientific editor work list.pdf